Abstract | Adenosine is a key endogenous molecule that regulates tissue function by activating four G-protein-coupled adenosine receptors: A 1 , A 2A , A 2B and A 3 . Cells of the immune system express these receptors and are responsive to the modulatory effects of adenosine in an inflammatory environment. Animal models of asthma, ischaemia, arthritis, sepsis, inflammatory bowel disease and wound healing have helped to elucidate the regulatory roles of the various adenosine receptors in dictating the development and progression of disease. This recent heightened awareness of the role of adenosine in the control of immune and inflammatory systems has generated excitement regarding the potential use of adenosine-receptor-based therapies in the treatment of infection, autoimmunity, ischaemia and degenerative diseases.
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. The authors found that when simple extracts of heart muscle and other tissues were injected intravenously into the whole animal they produced decreased heart rate and increased coronary blood flow. The active constituent of the extracts turned out to be adenosine, and since the 1980s adenosine has been used to slow down the heart of patients suffering from excessively increased heart rate caused by supraventricular tachycardia 2 . In addition, adenosine has been used as a diagnostic agent, that is, a coronary vasodilator, to assess coronary artery function in conjunction with radionuclide myocardial perfusion imaging 3 . Following the original discovery of the effects of adenosine on cardiac function, adenosine has been found to have regulatory roles in virtually every organ system studied.
Adenosine accumulates in the extracellular space in response to metabolic stress and cell damage
, and elevations in extracellular adenosine are found in conditions of ischaemia, hypoxia, inflammation and trauma 4, 5 . The rapid release of adenosine in response to tissue-disturbing stimuli has a dual role in modulating homeostasis. First, extracellular adenosine represents a pre-eminent alarm molecule that reports tissue injury in an autocrine and paracrine manner to surrounding tissue. Second, extracellular adenosine generates a range of tissue responses that can be generally viewed as organ protective thereby mediating homeostasis. Adenosine elicits its physiological responses by binding to and activating one or more of the four transmembrane adenosine receptors, denoted A 1 , A 2A , A 2B and A 3
. A prominent body of evidence supports the notion that the ability of adenosine, acting at its receptors, to control the immune and inflammatory systems plays a key role in the modulatory effects of adenosine in both health and disease. There are many promising emerging therapeutic approaches that are centred on the modulation of adenosine in the immune system. These encompass pharmacological compounds that interfere with the breakdown and generation of adenosine, as well as selective agonists and antagonists of various adenosine receptor subtypes (FIG. 1) . Some of these compounds are in preclinical investigations, whereas others have already entered clinical trials for various indications. In this Review, we provide a general overview of adenosine receptors, covering aspects of cell biology, molecular biology and pharmacology. Separate sections focus on the multitude of roles that adenosine has in dictating the function of cell types that are considered basic constituents of the innate and adaptive immune systems. Finally, we discuss the therapeutic basis of harnessing the adenosine receptor system in managing patients suffering from inflammatory, autoimmune and ischaemic diseases.
Adenosine receptor signalling A large body of evidence supports the view that adenosine receptors govern cell function by coupling to G proteins, although some G-protein-independent effects have also
An α-subunit of a heterotrimeric GTP-binding and GTP-hydrolysing protein (G protein) that inhibits the activity of a downstream enzyme such as adenylyl cyclase.
G s
An α-subunit of a heterotrimeric GTP-binding and GTP-hydrolysing protein (G protein) that stimulates the activity of a downstream enzyme such as adenylyl cyclase.
been reported 6 . Traditionally, adenosine receptor signalling is thought to occur through the inhibition or stimulation of adenylyl cyclase with a concomitant decrease or increase in intracellular cyclic Amp concentrations. Based on their ability to decrease or increase cAmp accumulation, adenosine receptors were initially classified as A 1 or A 2 receptors, respectively 7 . Subsequent studies have refined the classification of adenosine receptors and cAmp-increasing A 2 receptors have been divided into two groups: high-affinity A 2A receptors and low-affinity A 2B receptors 8 . The more recent discovery and characterization of A 3 receptors have made it clear that in addition to A 1 receptors, A 3 receptors dictate certain cellular responses such as rodent mast-cell degranulation, in part by decreasing intracellular cAmp concentrations 9 . This early picture of adenosine receptor signalling through the adenylyl cyclase-cAmp system has been substantially expanded, and it is now established that adenosine receptors can be linked to various other pathways. A 1 receptor activation had traditionally been linked to G i -mediated inhibition of adenylyl cyclase. However, it is now known to be also linked to various kinase pathways including protein kinase C (pKC), phosphoinositide 3 (pI3) kinase and mitogen-activated protein (mAp) kinases 10 . In addition, A 1 receptor activation can directly activate K + channels and inhibit Q-, p-and n-type Ca 2+ channels. It is noteworthy that most of these signalling pathways were uncovered in non-immune cell types, and A 1 receptor signalling mechanisms in cells of the immune system are not known.
A 2A receptors, similar to other G s -protein-coupled receptors, signal mainly by the adenylate cyclase-cAmpprotein kinase A (pKA) canonical pathway, but they can also signal through the activation of an exchange factor that is directly activated by cAmp (epac) 6 . Signalling downstream from pKA proceeds through phosphorylation of the transcription factor CReB on serine residue 133, resulting in its activation 11 . Activated CReB can mediate gene expression directly by interacting with gene promoters or indirectly by competing with nuclear factor-kB (nF-kB) or other transcription factors for an important cofactor, CBp 6 . In other cell types A 2A receptors have been shown to signal for increased collagen production by activating mAp kinases 12 and inhibiting neutrophil superoxide production by activating protein phosphatase 13 . Furthermore, recent results indicate that CeBpb is responsible for the stimulatory effect of A 2A receptor agonists on interleukin 10 (Il10) production by macrophages 14 (FIG. 2) . which of the outlined mechanisms mediate A 2A receptor signalling in the various immune cell types remains to be defined in more detail.
A 2B receptor stimulation can trigger adenylyl cyclase activation via G s and phospholipase C (plC) activation via G q (ReF. 15) . Cross-talk between these two pathways appears to be essential for the upregulation of Il4 production by human mast cells following A 2B receptor activation 16 . In particular, G q -mediated activation of plCb leads to calcium mobilization and an increase in NFATc1-dependent Il4 transcription, and this response is amplified by the G s -mediated accumulation of nFATc1 protein.
The classical signalling pathways associated with A 3 receptor activation comprise G i -mediated inhibition of adenylyl cyclase and G q -mediated stimulation of plC 17 . In addition, A 3 receptors can utilize the plD, RhoA, wnT, mAp kinase and pI3 kinase pathways in dictating cell function. In fact, A 3 receptor-dependent enhancement of histamine release in sensitized murine mast cells was prevented by inhibition of G i proteins using pertussis toxin and by pharmacological inhibition of pI3 kinase 18 .
Adenosine receptors on immune cells
Macrophages. The effect of adenosine on cytokine production by macrophages has attracted considerable attention, because macrophage-derived cytokines are crucial initiators and orchestrators of immune responses. As tumour necrosis factor-α (TnF-α) was one of the first cytokines to be discovered, a substantial body of information has accumulated regarding the ability of adenosine receptor activation to limit TnF-α production following Box 1 | Adenosine-receptor metabolism and signalling Extracellular adenosine levels increase following the release of adenosine from cells or as a result of extracellular catabolism of released adenine nucleotides. Intracellular adenosine, which can be derived from increased intracellular metabolism of ATP during cellular stress or S-adenosyl homocysteine, is liberated mainly via equilibrative nucleoside transporters. Extracellular ATP and ADP are catabolized by a cascade of ectoenzymes comprising CD39 (ENTPD1; ectonucleoside triphosphate diphosphohydrolase 1) and CD73 (ecto-5′-nucleotidase). CD39 is an enzyme that hydrolyses ATP and ADP to AMP, and CD73, in turn, rapidly dephosphorylates AMP to adenosine 126 . Owing to the ubiquitous presence of equilibrative nucleoside transporters, adenosine generated from extracellular ATP is rapidly taken up by cells from the extracellular space. Adenosine in the cytosol is then metabolized either by adenosine kinase to form AMP or adenosine deaminase, which deaminates adenosine to inosine 6, 127 . As a result of the rapid uptake and metabolism of adenosine, levels of this mediator are maintained low in unstressed, healthy tissues. However, under pathophysiological conditions adenosine removal can not keep pace with its generation, resulting in markedly increased extracellular adenosine concentrations.
All of the adenosine receptors contain seven transmembrane domains and couple to intracellular GTP-binding proteins (G proteins). Adenosine can activate A 1 , A 2A and A 3 receptors with EC 50 values that are between 0.01 mM and 1 mM, whereas A 2B receptor activation generally requires adenosine levels that exceed 10 mM (EC 50 of 24 mM) 128 . Because physiological adenosine concentrations are lower than 1 mM, physiological levels of adenosine can activate A 1 , A 2A and A 3 receptors, whereas A 2B receptor activation requires pathophysiological conditions 129 . Although the cellular responses to adenosine are highly dependent on the adenosine concentrations at the cell surface, several other factors, such as receptor density and the functionality of the intracellular signalling pathways coupled to adenosine receptors, are also key determinants in dictating the nature and magnitude of the effect of adenosine on the cell. For example, A 2A receptor activation potently suppresses the production of the T helper 1-inducing cytokine interleukin 12 (IL12) by monocytes that are preincubated with the pro-inflammatory cytokine IL1 or tumour-necrosis factor-α, agents that also upregulate A 2A receptors in these cells 119 . This example highlights the importance of receptor expression in defining the magnitude of the response to receptor stimulation. Furthermore, the effect of adenosine can also depend on the polarized localization of adenosine receptors. For example, A 3 adenosine receptors accumulate at the leading edge of migrating neutrophils and have an important role in facilitating the directional movement of cells in response to chemotactic stimuli 35 . Finally, caution should be exercised in interpreting data assessing adenosine receptor function in different species, because sequence variations in cloned adenosine receptors have been shown to be associated with varying pharmacological responses to selective agonists and antagonists. This is best illustrated by the fact that A 3 receptors remained undiscovered until they were cloned 130 , because the rodent A 3 receptor is insensitive to xanthines such as theophylline and caffeine, antagonists that had been extensively used in identifying adenosine receptor-mediated effects. macrophage activation. Recent studies using adenosinereceptor knockout mice have painted a detailed but still not complete picture of the receptors involved. Several studies agree that the A 2A receptor is the primary and dominant adenosine receptor subtype that mediates inhibition of TnF-α [19] [20] [21] . A role for other receptors was postulated based on the observation that adenosine, and the agonists neCA and IB-meCA (CF-101) can each inhibit, albeit to a lesser extent, TnF-α production even in A 2A -receptor knockout mice 19, 20 . A study using a combined approach of using A 2A -receptor knockout mice and the A 2B receptor antagonist mRS 1754 supports a role for A 2B receptors as the other inhibitory receptor 20 . However, it appears that A 2B receptors become operational only when their effect is not masked by A 2A receptors, because both mRS 1754 and genetic deletion of A 2B receptors in the presence of functional A 2A receptors fails to affect the suppression of TnF-α production 20, 21 . A similar picture is emerging regarding how adenosine receptor activation augments Il10 production. A key role for A 2A receptors was recently documented when adenosine failed to upregulate Escherchia coliinduced Il10 release by macrophages lacking A 2A receptors but not wild-type macrophages 14 . In the RAw264.7 
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NFATc1
NFATc1 is a member of the nuclear factor of activated T cells (NFAT) protein family, which are a family of transcription factors whose activation is controlled by calcineurin, a Ca 2+ -dependent phosphatase. They were originally identified in T cells as inducers of cytokine gene expression.
Pertussis toxin
A compound that inhibits the guanine nucleotide binding proteins G i and G o via ADP ribosylation.
Macrophage
One of the main types of professional phagocytes. Macrophages are long-lived and detrimental for many microbial pathogens. Intracellular bacteria can survive within the macrophages. They can mediate antibody-dependent cellular cytotoxicity through phagocytosis.
macrophage cell line, which expresses negligible levels of A 2A receptors, adenosine upregulates Il10 production via an A 2B -receptor-mediated mechanism 22 . while A 2B receptor activation has a minor impact on TnF-α and Il10 production, it is key to the stimulatory effect of adenosine on Il6 production, as neCA is unable to induce the release of Il6 in A 2B -receptor knockout but not wild-type macrophages 21 . Finally, it is important to emphasize that the issue of which adenosine receptors regulate cytokine production by human monocytes/macrophages is even more contentious with evidence pointing to the involvement of all four receptors 23 . These results, however, must be interpreted with caution, because they are based entirely on pharmacological approaches, and several of the ligands used, especially in early studies, are not particularly selective. nevertheless, the recent observations that human newborn plasma contains elevated concentrations of adenosine when compared with adult plasma, and degrading adenosine with adenosine deaminase or interrupting adenosine signalling by adenosine receptor blockade augments TnF-α production by neonatal but not adult blood, highlight the importance of the inhibitory effect of adenosine on TnF-α production in human immunity 24 . Based on these results it was speculated that adenosine might protect the fetus from excessive inflammatory responses that drive alloimmune reactions and premature delivery. However, this protective effect would come at a price of increased susceptibility to infections following birth.
Dendritic cells.
Although dendritic cell responses from adenosine-receptor knockout mice have yet to be characterized, available data from human studies support a consistent role for adenosine receptors in orchestrating dendritic cell function. G i -coupled (A 1 , A 3 or both depending on the experimental system) adenosine receptors are expressed on both immature myeloid 25 and plasmocytoid dendritic cells 26 , and their activation results in the mobilization of intracellular calcium from intracellular stores and reorganization of the actin cytoskeleton. Consistent with these adenosine-induced intracellular responses, immature dendritic cells migrate along different concentration gradients of adenosine, indicating that adenosine receptor activation induces chemotaxis in immature dendritic cells 25, 26 . These stimulatory responses induced by G i -coupled adenosine receptors can be observed only in immature dendritic cells, as these receptors undergo downregulation during dendritic cell maturation 25, 26 . Although A 2A receptors are present on immature dendritic cells, they are expressed at low levels and appear to be silent, as their activation is unable to elicit downstream signalling events such as accumulation of intracellular cAmp 25 . However, dendritic cell maturation is accompanied by the emergence of A 2A -receptor-mediated signalling responses, owing to both increased expression and coupling of A 2A receptors 25, 26 . A 2A receptor activation on mature dendritic cells shifts their cytokine profile from a pro-inflammatory to an anti-inflammatory one, with reduced Il12, Il6 and interferon-α (IFn-α) production and augmented Il10 production [25] [26] [27] . It is likely that dendritic cells in the presence of adenosine have a reduced capacity to induce T helper 1 (T H 1) cell versus T H 2 cell polarization of naive CD4 + cells 27 . This is due to the adenosine-induced switch in dendritic cell cytokine production away from the T H 1-inducing Il12 towards the T H 2-inducing Il10.
In summary, the available data support a dual role for adenosine in dictating dendritic cell function. Adenosine promotes the recruitment of immature dendritic cells to sites of inflammation and injury via A 1 or A 3 receptors. At these sites adenosine produces, via A 2A receptors, an anti-inflammatory dendritic cell phenotype driving T-cell responses towards a T H 2 profile.
Neutrophils.
Adenosine is a potent modulator of neutrophil function and it has long been appreciated that adenosine, by activating its receptors, regulates stimulated production of reactive oxygen species by these cells and phagocytosis [28] [29] [30] . Individual neutrophils do not produce large quantities of cytokines; however, because of the large numbers of accumulated neutrophils the cumulative contribution to pro-inflammatory cytokine levels at a given site is large. Adenosine, acting at A 2A receptors, regulates the production of a range of cytokines including TnF-α, 
Adenosine deaminase
Adenosine deaminase irreversibly deaminates adenosine, converting it to the related nucleoside inosine by the removal of an amino group.
Alloimmune reaction
Alloimmunity is an immune reaction against non-self material from the same species.
Dendritic cell
These professional antigenpresenting cells are increasingly recognized as having crucial immunoregulatory functions. They are found in various tissues where they take up antigens, process them, migrate to the lymph nodes and present the antigens to T cells.
CD4 + cells
Cells expressing the CD4 + glycoprotein that recognises major histocompatibility class II molecules.
T H 1 and T H 2 cells
The 
Antigenic stimulation
When the body's immune system responds to a foreign substance.
macrophage inflammatory protein (mIp)-1α (also known as CCl3), mIp-1b (CCl4), mIp-2α (CXCl2) and mIp-3α (CCl20) 31 . neutrophils are recruited to inflammatory sites by the post-capillary venular endothelium, which alters the expression of adhesive molecules on its surface to capture neutrophils from the circulation. Adenosine, via A 2A receptors, inhibits the adhesion of neutrophils to the endothelium by decreasing the expression and stickiness of the adhesion molecules expressed on neutrophils [32] [33] [34] . By contrast, A 1 receptors promote neutrophil adhesion to different adhesive molecules on the endothelium and on other surfaces 32 . once in the tissue neutrophils migrate along gradients of chemoattractants. There are many chemoattractants including activated complement components (C5a), bacterial products (formylated peptides) and chemokines, and studies have shown that adenosine promotes directed migration of neutrophils via A 1 and A 3 receptors [35] [36] [37] . In addition, neutrophils cluster their A 3 receptors at the leading edge of the cell and release ATp, which is converted at the cell surface to adenosine, which then acts in an autocrine manner to stimulate migration 35 . At inflamed sites neutrophils undergo apoptosis and adenosine, acting at A 2A receptors, prevents neutrophils from undergoing apoptosis [38] [39] [40] . Thus, virtually every function carried out by neutrophils is regulated by adenosine and its receptors.
Mast cells. The observation that inhaled adenosine provokes bronchoconstriction in individuals suffering from asthma but not in normal volunteers has propelled adenosine and adenosine receptors into the forefront of asthma research 41 . Although the mechanisms of how adenosine mediates bronchoconstriction are still elusive, there is overwhelming evidence that mast-cell mediators such as cytokines and histamine may have a key role in evoking airway constriction in response to adenosine. Although A 2A , A 2B and A 3 receptors are clearly present on the cell membrane of mast cells 42 , there is uncertainty regarding which receptor(s) account for the increased mast-cell activation following adenosine receptor activation.
Adenosine was recently documented to stimulate release of the major asthma-promoting cytokine Il13 by mouse mast cells that were obtained from wild-type but not A 2B -receptor-knockout mice. This result implies that A 2B receptors are the receptors involved in the proinflammatory effects of adenosine 43 . In addition, it is clear from genetic studies with knockout mice that A 3 but not A 2B receptor agonism can produce histamine release of lung mast cells in the absence of specific antigenic stimulation 18 . Thus, A 2B and A 3 receptors subserve different pro-inflammatory roles in naive mouse mast cells. The role of A 2B receptors in regulating antigen-stimulated histamine release in mouse mast cells is controversial. mast cells isolated from wild-type animals display decreased histamine release following stimulation with antigen when compared with mast cells obtained from A 2B -receptor knockout mice 44 . This observation was interpreted as indicating that constitutive activation of A 2B receptors on cultured mast cells suppresses the release of histamine. A subsequent study confirmed the increased degranulation of A 2B -deficient mast cells, but based on additional approaches the authors questioned this interpretation of A 2B -receptor-mediated decrease of degranulation of mast cells 43 . The reason for the different interpretation in the latter study was that exogenous adenosine maintained its stimulatory effect on histamine release in A 2B -receptor knockout mast cells 43 . In addition, no evidence of constitutive activity of A 2B receptors was revealed by studies using inverse agonists and measuring intracellular cAmp levels. Thus, it appears likely that the decreased release of histamine by mast cells isolated from A 2B receptor wildtype versus knockout mice reflects an altered responsiveness of A 2B receptor wild-type versus knockout cells to antigen. This is possibly from altered development of mast cells in A 2B -receptor-knockout mice. unlike A 2B receptors, A 3 receptors directly control histamine release by antigen-stimulated mouse mast cells, because the stimulatory effect of exogenous adenosine noted in wildtype mast cells is not observed in A 3 -receptor-knockout mast cells 45 .
In canine and human mast cells, degranulation or cytokine release appears to be mediated primarily by A 2B receptor activation 46, 47 . A 2B receptor stimulation in human mastocytoma HmC-1 cells induces secretion of the T H 2 cytokines Il4 and Il13, as well as a number of other proinflammatory cytokines such as Il1b and Il8. Although it is not clear whether adenosine receptor activation is able to stimulate the degranulation of human mast cells 44 , the observation of increased Il4 and Il13 production following adenosine receptor activation strongly implicates human mast-cell adenosine receptors as important players in the pathophysiology of human asthma.
Lymphocytes. In addition to regulating lymphocyte function indirectly by stimulating adenosine receptors on innate immune cells such as dendritic cells, adenosine can also directly affect lymphocyte responses by binding and activating adenosine receptors on lymphocytes. A number of recent studies using adenosine-receptor-knockout mice have evaluated the effect of adenosine receptor activation on various lymphocyte functions. The consensus emerging from these studies, as well as pharmacological studies, is that A 2A receptors are the dominant adenosine receptors in dictating lymphocyte responses.
Studies using A 2A -knockout models have shown that A 2A receptor activation inhibits Il2 secretion 48 by naive CD4 + T cells thereby reducing their proliferation 49 following T-cell receptor stimulation. A 2A receptor activation also suppresses the production of both IFn-g and Il4 by both naive CD4 + T cells 48, 50 and polarized T H 1 and T H 2 cells . However, the production of neither TC1 (IFn-g) nor TC2 (Il4 and Il5) cytokines was influenced by A 2A receptor activation. In addition, pharmacological A 2A receptor activation failed to reduce TC1 or TC2 cell cytolytic function 52 , which suggests that another subtype, possibly the A 3 receptor, may mediate the anti-cytotoxic effect of adenosine noted in prior studies 53, 54 . In contrast to these results with CD8
+ cytotoxic cells, recent data with A 1 -, A 2A -and A 3 -receptor-knockout mice support a primary role for A 2A receptors in preventing the cytolytic activity of Il2-activated natural killer (nK) cells 55 . Recent studies have revealed an important role for adenosine in mediating the immune suppressive properties of regulatory T (T Reg ) cells, a cell type that is thought to have a key role in keeping the immune system at bay, thereby preventing excessive tissue injury (FIG. 3) 
MHC molecules
Originally named because they function as transplantation antigens. MHC molecules have a crucial role in antigen presentation, and serve as accessory binding proteins for T-helper and T-killer cells.
the pathophysiology of asthma and chronic obstructive pulmonary disorder (CopD). Adenosine receptors on immune cells contained in the lung appear to have particularly important roles. most compelling are the observations that inhaled adenosine can induce bronchoconstriction in patients suffering from asthma or CopD, but not in healthy individuals, and adenosine receptor blockade can prevent this bronchoconstrictive response 42 . These observations, combined with the demonstration that both adenosine levels and adenosine receptor expression on immune cells in the lung are elevated in patients with asthma and CopD, implicate endogenous adenosine as a prominent signalling molecule in lung diseases. As the bronchoconstrictive response to adenosine can be blocked by mast-cell membrane-stabilizing agents that can prevent the release of injurious mast-cell mediators, and because histamine receptor antagonists are also effective against adenosine, one major hypothesis explaining the mechanism of adenosine-mediated bronchoconstriction centres around a key role played by mast cells 42 . This general scheme of the injurious role of adenosine receptor activation on mast cells has been reinforced by studies using rodent models of asthma. These studies have also identified A 2B (ReF. 43) and A 3 (ReFs 18,45) receptors as the main contributors that mediate the stimulatory effect of adenosine on mast-cell activation. Although there is a paucity of human in vivo studies detailing the role of adeno sine receptor subtypes in asthma and CopD, in vitro studies using human mast cells have narrowed down the candidate adenosine receptors to the A 2B receptor (FIG. 4) . In addition to mast cells, pro-inflammatory effects of A 2B stimulation have also been observed with human bronchial smooth-muscle cells 64 , human bronchial epithelial cells 65 and human lung fibroblasts 66 , which respond to adenosine by increased release of Il6 (ReFs 64, 66) and Il19 (ReF. 65) . A 2B receptor activation on human lung fibroblasts promotes their differentiation into myofibroblasts that are capable of overproducing extracellular matrix 66 , which suggests that adenosine may participate in the fibrosis and remodelling of the lung during asthma and CopD.
This substantial evidence documenting the proinflammatory effects of selective A 2B receptor activation in human and rodent cellular systems combined with the utility of A 2B receptor antagonism in preventing disease progression in rodent animal models 67, 68 suggest that A 2B antagonists may be a viable treatment option for the management of asthma and CopD in human patients. Indeed, it is now well established that enprofylline, an anti-asthmatic agent, is a relatively selective (albeit not potent) A 2B receptor antagonist 69 . The selective A 2B receptor antagonist CvT-6883 (ReFs 67, 68) , which has shown efficacy in preventing disease in rodent models of asthma and CopD, appeared to be safe and well tolerated in a recent phase I study, raising hopes that this agent might have utility in the treatment of individuals suffering from asthma and CopD (TABLe 1) .
lung inflammation results in the accumulation of neutrophils and other leukocytes in the interstitial space and in the airway. This is accompanied by an increased microvascular permeability and the release of chemotactic cytokines. A 2A agonists have been found to reverse these effects. To determine which pulmonary cells respond to A 2A receptor activation, pulmonary inflammation has been assessed in wild-type and A 2A -receptor-knockout mice 70 . To differentiate the role of A 2A receptors on haematopoietic and parenchymal cells, chimeric mice were created by transfer of bone marrow between wild-type and A 2A receptor knockout mice. In wild-type mice, A 2A receptor activation reduces lipopolysaccharide-induced neutrophil recruitment and release of cytokines. pretreatment, but not post-treatment, also reduces the increase in vascular permeability. A 2A receptor activation only reduced lung inflammation when the A 2A receptor was present on bonemarrow-derived cells. In addition, using A 2A -receptorknockout mice, the adenosine-A 2A receptor-cAmp axis was identified as a potent endogenous anti-inflammatory signalling pathway that reduces airway reactivity and inflammatory-cell infiltration following sensitization with ragweed 71 . Thus, A 2A agonists appear to be effective at curbing inflammatory lung tissue damage. However, in clinical trials, the utility of the A 2A agonist Gw328267X was limited by cardiovascular side effects 72 (TABLe 1) .
Ischaemia. During reperfusion following ischaemic injury, many tissues have been shown to be protected from reperfusion injury owing to the activation of A 2A receptors on bone-marrow-derived cells (FIG. 5) . These include liver 73 , kidney 74 , heart 75 , skin 76 , spinal cord 77, 78 and lung 79 . In liver and kidney tissues inKT cells have been found to be sensitive to A 2A receptor activation and to have a crucial role in initiating an inflammatory cascade during reperfusion injury. These cells are rapidly stimulated to produce IFn-g within 2 hours after the initiation of reperfusion, and the use of antibodies to deplete nK1.1-positive cells (nK and Figure 4 | A 2B receptor activation has broad pro-inflammatory actions by stimulating the pro-inflammatory functions of a variety of cell types that mediate asthma. A 2B receptor activation increases interleukin 6 (IL6) production by pulmonary fibroblasts, which in turn leads to increased generation of myofibroblasts, which are capable of depositing extracellular matrix. A 2B receptor activation promotes the production of pro-inflammatory factors by mast cells and stimulates mast-cell degranulation. Increased IL4 production following mast cell A 2B receptor activation leads to increased immunoglobulin E (IgE) production by B cells. bFGF, basic fibroblast growth factor; MCP1, monocyte chemoattractant protein 1; VEGF, vascular endothelial growth factor.
Invariant NKT (iNKT) cells
A rare subset of lymphocytes that expresses an invariant T-cell receptor that recognizes certain glycolipids when bound to the major histocompatibility complex class I-like molecule, CD1d. Through secretion of cytokines they are powerful modulators of adaptive immune responses.
Cecal ligation and puncture
An experimental model of polymicrobial sepsis that is generally considered more relevant to the human disease than rodents injected with bacterial lipopolysaccharide (endotoxin).
inKT) or to block CD1d-mediated lipid-antigen presentation to inKT cells replicates, but is not additive to the protection from reperfusion injury afforded by A 2A adenosine receptor activation 62, 80 . liver reperfusion injury is also reduced in Rag1-knockout mice that lack mature lymphocytes, and can be restored to the level seen in wildtype mice by adoptive transfer of inKT cells purified from wild-type or A 2A receptor knockout mice, but not IFn-gknockout mice Arthritis. Despite the introduction of a number of effective biological agents for the treatment of rheumatoid arthritis over the past decade methotrexate remains one of the most effective and most commonly used therapies for inflammatory arthritis. Although originally introduced for the treatment of cancer as a folic acid analogue, the mechanism by which methotrexate, at very low dosages (average dosage in the united States, 17.5 mg per week for rheumatoid arthritis versus as much as 5 g per week for cancer), diminishes inflammation differs from the anti-proliferative mechanism of the drug. At low doses methotrexate is taken up by cells and polyglutamated to a long-lasting metabolite 81 . methotrexate polyglutamates have a different spectrum of enzyme inhibition and AICAR transformylase, an enzyme that is part of the de novo purine synthetic pathway, appears to be most sensitive to inhibition by methotrexate polyglutamates 82 . At low doses of methotrexate, this leads to the intracellular accumulation of AICAR 83, 84 . AICAR is a competitive inhibitor of Amp deaminase leading, ultimately, to enhanced adenosine release from cells 83 . Although it is difficult to measure adenosine levels in biological fluids owing to the short half-life (2-8 seconds) of adenosine in blood and other fluids 85 in patients with rheumatoid arthritis treated with methotrexate there is strong evidence that methotrexate therapy promotes adenosine release 86, 87 .
Studies in mice and rats demonstrate that the anti-inflammatory effects of methotrexate are mediated by adenosine and that the anti-inflammatory effect of methotrexate is lost if animals are treated with adenosine receptor antagonists or if their adenosine A 2A or A 3 receptors have been deleted [88] [89] [90] [91] [92] [93] [94] . Similar loss of methotrexate efficacy has been noted in patients with rheumatoid arthritis who ingest significant quantities of caffeine, an adenosine receptor antagonist 95 . Thus, by promoting adenosine release at inflamed sites methotrexate diminishes inflammation in patients with rheumatoid arthritis. Building on the observation that methotrexate exerts some of its beneficial effects via A 3 receptors, coupled with the finding that the selective A 3 receptor agonist IB-meCA ameliorates the course of arthritis in mouse models [96] [97] [98] , IB-meCA was recently tested in a phase II trial in patients with rheumatoid arthritis. IB-meCA was safe and well tolerated, and patients treated with this drug achieved a moderate reduction of symptoms 99 (TABLe 1) . methotrexate and IB-meCA have additive anti-inflammatory effects in rat adjuvant arthritis, which are mediated by an upregulation of the expression of A 3 receptors on inflammatory cells 100 . Sepsis. preclinical studies using both knockout and pharmacological approaches have provided insights into the role of the various adenosine receptors in the physiological response of the organism to sepsis 101 . Inactivation of A 1 receptors increased mortality in intra-abdominal sepsis provoked by cecal ligation and puncture in mice, an effect that was correlated with heightened inflammationinduced hepatic and renal injury 102 . These results suggest that A 1 receptor activation may have a beneficial effect and additional studies testing the efficacy of A 1 receptor agonists are warranted. Similar to results with A 1 receptor blockade in cecal ligation and puncture, both knockout and pharmacological antagonism of A 3 receptors increased mortality, whereas stimulation of A 3 receptors with IB-meCA was protective 103 . In contrast to observations with blockade of A 1 and A 3 receptors, A 2A receptor inactivation by either gene deletion or administration of Zm241385 prevented cecal ligation and puncture-induced mortality by a mechanism that involved decreased bacterial dissemination that appeared to be secondary to sustained immune system function 104 . paradoxically, A 2A receptor activation, when combined with antibiotics, has been noted to reduce mortality from sepsis induced 
Angiogenesis
The growth of new blood vessels from pre-existing vessels. Angiogenesis is a normal process in growth and development but it also a fundamental process required for the growth of tumours.
by injecting with live E. coli, possibly by suppressing an exaggerated inflammatory response that can result from the rapid drug-induced killing of large numbers of bacteria 105 . Recent preliminary studies evaluating the role of A 2B receptors have demonstrated an anti-inflammatory and protective role of A 2B receptor stimulation in cecal ligation and puncture (C. Csoka, G. Hasko, Z. H. nemeth and p. pacher, unpublished observations).
Inflammatory bowel disease.
Crohn's disease and ulcerative colitis are chronic, relapsing inflammatory bowel diseases (IBDs) that are characterized by a dysfunction of mucosal T cells, imbalanced cytokine production and cellular inflammation leading to damage of the intestinal mucosa. Although the aetiology of IBD remains to be determined, recent studies suggest that disease results from an inappropriately regulated immune response to luminal antigens in a genetically susceptible host 106 . CD4 + CD25
+ T Reg cells have emerged as master regulators of the inflammatory response of the mucosa in IBD and have also been documented to offer a therapeutic option in severe inflammatory colitis 107 . Studies have highlighted the protective effects of A 2A receptor activation in various animal models of colitis, and these protective effects can be ascribed to two major mechanisms: decrease of inflammatory-cell infiltration and function in the mucosa, and increased activity of T Reg cells. The first mechanism is supported by evidence that A 2A receptor activation by ATl146e (an A 2A receptor agonist) decreases both leukocyte infiltration and the production of inflammatory cytokines by disease-inducing T-effector cells 108 . 110 prompted recent studies assessing the effect of A 2B receptor blockade in IBD. Administering ATl-801, a selective A 2B antagonist, to mice suffering from colitis markedly decreased Il6 production and neutrophil infiltration, and reduced the extent of mucosal damage thereby ameliorating the course of disease 111 . This pro-inflammatory role of A 2B receptor activation by endogenous adeno sine was recently confirmed using A 2B -receptor-knockout mice 112 , confirming that blockade of A 2B receptor represents a potentially advantageous treatment option that selectively targets the gut for patients afflicted with IBD. This proposition is predicated on the findings that A 2B receptor expression is highest in the gut when compared with other organs and that levels of endogenous adenosine that appear to perpetuate the disease process through A 2B receptors are elevated mostly locally in the gut 111 .
Wound healing. In the skin, inflammation is part of a continuum in which injured tissue is repaired and replaced resulting in wound healing. montesinos et al. first reported that topical application of adenosine A 2A receptor agonists increases the rate of wound healing in normal mice and in diabetic rats 113 . Increases in matrix and vessel formation were induced by adenosine receptor agonists and the improvement in the rate of wound healing was significantly greater than that induced by recombinant platelet-derived growth factor [113] [114] [115] [116] . A 2A and A 2B receptor stimulation increases angiogenesis both directly and indirectly: adenosine receptors directly stimulate microvascular endothelial cell-proliferation as well as the autocrine production of vascular endothelial growth factor (veGF), a central stimulus for endothelial proliferation and angiogenesis [117] [118] [119] , and inhibit the production of thrombospondin 1, an anti-angiogenic matrix . In addition, adenosine stimulates veGF production by macrophages 116, 121, 122 . moreover, A 2A and A 2B receptor stimulation promotes matrix production by skin fibroblasts, an essential step in tissue repair 66, [123] [124] [125] . In this context, it is noteworthy that A 2A -receptor-deficient mice do not form granulation tissue indicating that endogenous adenosine plays a central role in wound healing 114 . Sonedenoson (mRe0094), an A 2A agonist that regulates the inflammatory response and enhances tissue regeneration, is currently undergoing trials for the treatment of diabetic foot ulcers (TABLe 1) .
Conclusions
The adenosine receptor system has evolved as both a rapid sensor of tissue injury and the major 'first-aid' machinery of tissues and organs. Adenosine receptor activation thus preserves tissue function and prevents further tissue injury following an acute injurious insult, such as reperfusion injury, actions in which the immune system has a paramount role. This primordial protective function of the adenosine receptor system following acute insults can, however, be overshadowed by its reduced ability to protect against chronic insults. In addition, in certain chronic disease states, such as asthma, the adenosine receptor system can even exacerbate tissue dysfunction.
Recent advances in understanding the role of the distinct adenosine receptors and the complex network of cellular players that determine the adenosine response to tissue injury have helped identify novel pharmacological targets to restore tissue function in various diseases
. Despite growing enthusiasm regarding these targets, it is important to emphasize that because most of the data were obtained using animal models, caution should be exercised in translating results to the clinic. potential difficulties in translating results may stem from, in part, species differences and the fact that animal studies generally are done in young, relatively healthy animals over a short time-span. of particular relevance is species differences in adenosine signalling in asthma studies. In rodents, primed mastcell degranulation appears to be mediated primarily by A 3 receptors, whereas in humans A 2B receptors are more important.
Although adenosine receptor agonists have power ful immunomodulatory actions, the wide tissue distribution of adenosine receptors may limit their usefulness in the treatment of inflammatory diseases. Adenosine receptor antagonists, however, represent an ideal target for the therapy of certain immune-related disorders because their action is selectively targeted to the site of injury, where endogenous adenosine is released. Similarly, interfering with the function of enzymes and transporters that are responsible for the accumulation of extracellular adenosine allows local targeting of adenosine receptors, providing an opportunity for interventions with limited side effects. It is clear that a better understanding of adenosine receptor function will be required before the enormous potential of adenosine-based therapies can be realized to ease human suffering. 
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